Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
Quick Takeaways: Why It Matters? Elanco is extending its Advantage franchise into the collar segment with an over‑the‑counter, one‑size, water‑resistant dog collar that kills fleas and ticks and repels mosquitoes for four months, meaning most pets need only three collars per ye...
Quick Takeaways: Why It Matters? APVMA approval gives Elanco a timely first international expansion for Credelio Quattro under the Advocate franchise, letting it leverage strong brand equity to capture share in Australia’s highly competitive, vet‑d...
